FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Company’s HIFU
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT FocalTherics ™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT AUSTIN, Texas, July 30, 2026 (GLOBE NEWSWIRE)
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced the
FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical AUSTIN, Texas, June 16, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced that it has
EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026 Company Intends to Report and Classify its Legacy
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4 th, 2026 AUSTIN, Texas, May 21 th, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of
EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year 53% Growth in First Quarter U.S.
